Altering tumor microenvironment may reduce relapses after leukemia immunotherapy
Manipulating the immune system to treat cancer has generated phenomenal responses in some patients, including complete cures, but those responses do not last for everyone. For example, chimeric ...
Nature14y
VEGF and ephrin-B2: a bloody duo
Two independent studies show that ephrin-B2 controls the internalization and signaling of two types of vascular endothelial growth factor (VEGF) receptors—thereby regulating VEGF-induced ...
The American Journal of Managed Care13d
Enhancing Retinal Disease Outcomes With Anti-VEGF Therapies
New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...
Nature4mon
Sunitinib versus interferon-α in metastatic RCC
This inactivation ultimately causes increased secretion of VEGF. 1 Two phase III studies—Avastin for Renal Cell Cancer (AVOREN) 7 and Cancer and Leukemia Group B (CALGB) 90206 8 indicated ...